Genentech Announces FDA Emergency Use Authorization for Chugai’s Actemra for Hospitalized Patients with COVID-19
2021-06-25 · Chugai Pharmaceutical · original chugai-pharm.co.jp ↗
TOKYO, June 25, 2021 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Genentech issued a press release on June 24 (local time) regarding the Emergency Use Authorization by the US FDA for Actemra ® , a humanized anti-human IL-6 receptor monoclonal antibody [generic name: tocilizumab (genetical recombination)] created by Chugai, for the treatment of COVID-19 in hospitalized adults and children. Please refer to the link below for details of the press release: Genentech’s Actemra Receives FDA Emergency Use Authorization for the Treatment of COVID-19 In Hospitalized Adults and Children https://www.gene.com/media/press-releases/14917/2021-06-24/genentechs-actemra-receives-fda-emergenc Trademarks used or mentioned in this release are protected by laws.
The release as fetched from its publisher. chugai-pharm.co.jp ↗